Table 3 Anti-TB drug resistance, patients’ history of previous TB treatment and HIV status stratified for M. tuberculosis lineages
M. tuberculosislineages (n) | Anti-TB drugs resistance | PT N (%) | HIV + N (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | INH N (%) | RMP N (%) | STM N (%) | EMB N (%) | PZA N (%) | MDR N (%) | RFLD N (%) | Â | Â |
Dehli/CAS (95) | 10(10.0) | 3(3.3) | 10(10.5) | 7(7.4) | 2 (2.1) | 2 (2.1) | 2 (2.1) | 19 (20.0) | 24(25.3) |
Ethiopia_3 (32) | 10(31.0) | 3(9.4) | 6(18.8) | 5(15.6) | 4 (12.5) | 3(9.4) | 3(9.4) | 7(21.9) | 4(12.5) |
Haarlem (21) | 7(33.33) | 7(33.3) | 6(28.6) | 6(28.6) | 5 (23.8) | 7 (33.3) | 4 (19.0) | 2(9.5) | 7(33.3) |
Ethiopia_1 (19) | 1 (5.3) | 0 | 1(5.3) | 0 | 1(5.3) | 0 | 0 | 5 (26.3) | 4(21.1) |
Ethiopia_H37Rv like (17) | 2(11.8) | 0 | 1(5.9) | 0 | 0 | 0 | 0 | 3(17.6) | 6(35.3) |
Ethiopia_2 (9) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1(11.1) | 1(11.1) |
URAL (8) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 (37.5) |
LAM (8) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 (25.0) |
TUR (5) | 2 (40.0) | 0 | 1(20.0) | 0 | 0 | 0 | 0 | 1(20.0) | 2 (40.0) |
X-type (3) | 1(33.3) | 0 | 1(33.3) | 0 | 0 | 0 | 0 | 0 | 2(66.7) |
S-type (2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Beijing (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
UgandII (1) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Not defined (23) | 1 (4.3) | 1(4.3) | 0 | 0 | 0 | 0 | 0 | 5(21.7) | 7(30.4) |
Total (244) | 34 (13.9) | 14(5.7) | 26(10.7) | 18 (7.4) | 12 (4.9) | 12 (4.9) | 9(3.7) | 43(17.6) | 62(25.4) |